MQS Management LLC Makes New Investment in Bristol Myers Squibb Company $BMY

MQS Management LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,752 shares of the biopharmaceutical company’s stock, valued at approximately $405,000.

A number of other institutional investors have also modified their holdings of BMY. Brighton Jones LLC increased its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. GAMMA Investing LLC increased its position in Bristol Myers Squibb by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock valued at $2,420,000 after acquiring an additional 6,267 shares during the period. Guardian Asset Advisors LLC purchased a new stake in Bristol Myers Squibb during the 1st quarter valued at approximately $204,000. Aljian Capital Management LLC lifted its position in Bristol Myers Squibb by 29.4% during the 1st quarter. Aljian Capital Management LLC now owns 20,866 shares of the biopharmaceutical company’s stock worth $1,273,000 after acquiring an additional 4,745 shares during the period. Finally, Sovran Advisors LLC grew its stake in shares of Bristol Myers Squibb by 39.4% in the 1st quarter. Sovran Advisors LLC now owns 6,839 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 1,932 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 0.0%

Shares of BMY opened at $43.84 on Monday. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm has a market capitalization of $89.24 billion, a P/E ratio of 17.68, a PEG ratio of 2.29 and a beta of 0.33. The firm’s 50-day moving average is $45.75 and its two-hundred day moving average is $47.05.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analyst Weigh In

BMY has been the subject of several recent research reports. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a report on Tuesday, August 5th. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the stock. According to data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $57.23.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.